A kit for the prognosis of colorectal cancer

Patent metadata

Field	Value
Publication number	US-2016177399-A1
Application number	US-201414893394-A
Country	US
Kind code	A1
Filing date	May 20, 2014
Priority date	May 21, 2013
Publication date	Jun 23, 2016
Grant date	—

Abstract

A kit for the prognosis of colorectal cancer, which includes reagents related in detecting the expression level of any one or more genes of the following five genes: BST1, as shown in SEQ ID NO:1; MGST1, as shown in SEQ ID NO:2, 3, 4, 5, 6, 7, 8, 9 or 10; HP, as shown in SEQ ID NO:11 or 12; RCAN3, as shown in SEQ ID NO:13, 14, 15, 16, 17, 18, 19, 20, 21 or 22; and SRA1, as shown in SEQ ID NO:23 or 24. The reagents are used to detect the expression level of any one or more of the above five genes in the preparation of a kit for the prognosis of colorectal cancer. The kit can be used to perform precise prognosis for a patient suffering from colorectal cancer, and has good clinical application prospects.

First claim

1 . A kit for the prognosis of colorectal cancer, wherein it comprises reagents for detecting the expression level of any one or more genes selected from the following five genes: BST1, as shown in SEQ ID NO:1; MGST1, as shown in SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9 or 10; HP, as shown in SEQ ID NO: 11 or 12; RCAN3, as shown in SEQ ID NO: 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22; and SRA1, as shown in SEQ ID NO: 23 or 24.

2 . The kit according to claim 1 , wherein the reagents are reagents for detecting the amount of RNA transcribed from the gene.

3 . The kit according to claim 2 , wherein the reagents are reagents for detecting the amount of cDNA complementary to the mRNA.

4 . The kit according to claim 3 , wherein the reagents are reagents for detecting the amount of cRNA complementary to the cDNA.

5 . The kit according to claim 2 , wherein the reagents comprise a probe.

6 . The kit according to claim 1 , wherein the reagents are reagents for detecting the amount of polypeptide encoded by the gene.

7 . The kit according to claim 6 , wherein the reagents comprise an antibody, an antibody fragment, or an affinity protein.

8 - 14 . (canceled)

15 . A method for detecting gene expression in a human sample, comprising:
(1) determining the level of RNA transcribed from any one or more genes in a blood sample of a subject selected from the following group of genes: BST1, as shown in SEQ ID NO: 1; MGST1, as shown in SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9 or 10; HP, as shown in SEQ ID NO: 11 or 12; RCAN3, as shown in SEQ ID NO: 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22; and SRA1, as shown in SEQ ID NO: 23 or 24; and (2) detecting the gene expression in the blood sample of the subject.

16 . The method according to claim 15 , wherein in the step (1) the levels of RNAs transcribed from the five genes in the group are determined.

17 . The method according to claim 15 , wherein the sample is a blood sample of a patient suffering from colorectal cancer.

18 . The method according to claim 15 , wherein at least one oligonucleotide is used in the step (1).

19 . The method according to claim 18 , wherein one oligonucleotide only hybridizes with RNA transcribed from one gene, and/or can hybridize with cDNA complementary to the RNA transcribed from the gene.

20 . The method according to claim 19 , wherein said step (1) comprises the following steps:
(a) amplifying RNA transcribed from the gene, so as to obtain an amplified product; (b) detecting the amount of the amplified product obtained in step (a) by using at least one primer.

21 . The method according to claim 20 , wherein said step (1) comprises the following steps:
(i) using at least one probe to hybridize with cDNA which is complementary to the RNA transcribed from the gene, so as to obtain a hybridization product; (ii) detecting the amount of the hybridization product obtained in step (i).

22 . The method according to claim 15 , wherein the step (1) comprises a process for amplifying the RNA transcribed from the gene.

23 . The method according to claim 15 , wherein the step (1) comprises a process for detecting the amount of cDNA which is complementary to the RNA transcribed from the gene.

24 . The method according to claim 15 , wherein at least one probe is used in the step (1).

25 . The method according to claim 15 , wherein at least one primer is used in the step (1).

26 . An oligonucleotide, which only hybridizes with RNA transcribed from one gene, and/or, which can hybridize with cDNA complementary to the RNA transcribed from the gene selected from a group consisting of BST1, as shown in SEQ ID NO: 1; MGST1, as shown in SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9 or 10; HP, as shown in SEQ ID NO: 11 or 12; RCAN3, as shown in SEQ ID NO: 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22; and SRA1, as shown in SEQ ID NO: 23 or 24.

27 . The oligonucleotide according to claim 26 , wherein it is selected from the nucleotide sequences as shown in SEQ ID NOs: 25-34.

28 . A kit for detecting gene expression in a human sample, wherein it comprises specific partners corresponding to the five expression products of the following five genes: BST1, as shown in SEQ ID NO: 1; MGST1, as shown in SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9 or 10; HP, as shown in SEQ ID NO: 11 or 12; RCAN3, as shown in SEQ ID NO: 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22; and SRA1, as shown in SEQ ID NO: 23 or 24, and each partner specifically binds to one gene, respectively.

29 . The kit according to claim 28 , wherein the specific partners comprise an oligonucleotide.

30 . The kit according to claim 29 , wherein the specific partners are selected from a set of nucleotide sequences as shown in SEQ ID NOs: 25-34.

31 . The kit according to claim 30 , wherein the specific partners include an antibody and/or an affinity protein.

32 . A method for prognosis of development situation of a patient suffering from colorectal cancer by detecting a blood sample, wherein it comprises the following steps:
a) obtaining a blood sample, and detecting the amount of expression product of any one or more genes selected from the following five genes: BST1, as shown in SEQ ID NO: 1; MGST1, as shown in SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9 or 10; HP, as shown in SEQ ID NO: 11 or 12; RCAN3, as shown in SEQ ID NO: 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22; and SRA1, as shown in SEQ ID NO: 23 or 24; b) inputting the amount of the expression product of the gene detected in the step a) into a support vector machine model, and calculating a prognosis index; and c) evaluating the prognosis of the patient suffering from colorectal cancer based on the result obtained in step b).

33 . The method according to claim 32 , wherein in the step a) the amount of expression product of each gene in the five genes is detected.

34 . The method according to claim 32 , wherein in the step a), the amount of expression product of at least one gene is detected by contacting the expression product of said gene with the specific partner of the expression product.

35 . The method according to claim 32 , wherein in step a) for detecting the amount of expression product of a gene, the nucleotide sequences of the genes are selected from a set of sequences as shown in SEQ ID NOs: 1-24.

36 . The method according to claim 32 , wherein the expression product in step a) comprises at least one RNA transcript or one polypeptide.

37 . The method according to claim 32 , wherein the expression product comprises at least one mRNA.

38 . The method according to claim 36 , wherein the RNA transcript is detected and quantified by hybridization, amplification or sequencing.

39 . The method according to claim 36 , wherein the RNA transcript is brought into contact with at least one probe and/or at least one primer under a preset condition allowing hybridization of the probe and/or primer with the RNA transcript.

40 . The method according to claim 39 , wherein the cDNA of the RNA transcript is brought into contact with at least one probe and/or at least one primer under the preset condition allowing hybridization of the probe and/or primer with the cDNA.

41 . The method according to claim 36 , wherein the detection of the polypeptide is implemented by contacting the pol

Assignees

• Biomerieux Sa

Inventors

• Meng Xia
• Xu Qinghua
• Ye Xun
• Liu Fang
• Wu Fei

Classifications

• G01N33/57535

  of the large intestine, e.g. colon, rectum or anus · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/112

  Disease subtyping, staging or classification · CPC title

• C12Q2600/158

  Expression markers · CPC title